Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep 9;7(1):315.
doi: 10.1038/s41392-022-01165-x.

The interferon-γ receptor pathway: a new way to regulate CAR T cell-solid tumor cell adhesion

Lingjuan Hong  1 , Lupeng Ye  2
Affiliations
Comment

The interferon-γ receptor pathway: a new way to regulate CAR T cell-solid tumor cell adhesion

Lingjuan Hong et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Schematics of the IFNγR signaling pathway was required for sufficient cell adhesion between CAR T and solid tumor cells. a A schematic of the functional IFNγR signaling pathway mediates sufficient cell adhesion by modulating CAR T cell-binding duration and avidity. High-frequency interaction between ICAM-1 and LFA-1 stabilizes the immunologic synapse, which induces effective cytotoxicity of CAR T cells against solid tumors. b A schematic of the dysfunctional IFNγR signaling pathway renders solid tumors more resistant to CAR T cell killing due to insufficient cell adhesion. Reduced ICAM-1 expression leads to the suboptimal immunologic synapse formation, which reduces CAR T cell killing against solid tumors
See this image and copyright information in PMC

Comment on

  • CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
    Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, Scarfó I, Leick MB, Grauwet K, Berger TR, Stewart K, Anekal PV, Jan M, Joung J, Schmidts A, Ouspenskaia T, Law T, Regev A, Getz G, Maus MV. Larson RC, et al. Nature. 2022 Apr;604(7906):563-570. doi: 10.1038/s41586-022-04585-5. Epub 2022 Apr 13. Nature. 2022. PMID: 35418687

References

    1. Larson RC, et al. CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours. Nature. 2022;604:563–570. doi: 10.1038/s41586-022-04585-5. - DOI - PubMed
    1. Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 2019;25:1341–1355. doi: 10.1038/s41591-019-0564-6. - DOI - PubMed
    1. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 2020;17:147–167. doi: 10.1038/s41571-019-0297-y. - DOI - PMC - PubMed
    1. Kantari-Mimoun C, et al. CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNgamma and ICAM-1. Cancer Immunol. Res. 2021;9:1425–1438. doi: 10.1158/2326-6066.CIR-20-0837. - DOI - PubMed
    1. Yan X, et al. Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Signal Transduct. Target Ther. 2022;7:98. doi: 10.1038/s41392-022-00915-1. - DOI - PMC - PubMed

Publication types

Substances